What is known and objectives: Voriconazole is a triazole antifungal agent and is extensively metabolized via cytochrome P450 (CYP450); therefore, special precautions need to be taken when co-administered with a known CYP450 inducer, which may lead to treatment failure. The influence of some CYP450 inducers on the pharmacokinetics of voriconazole has been described in previous studies, but a systematic review was lacking. In this study, we carried out a systematic review to assess the influence of CYP450 inducers on the pharmacokinetic (PK) parameters of voriconazole. Methods: Pubmed, Embase, Cochrane Library, Clinicaltrials.gov and three Chinese databases (CNKI, CBM and WanFang) were searched through January 2016. Interventional and observational studies comparing the PK parameters of voriconazole used alone or with CYP450 inducers in healthy volunteers and patients were included. The outcomes included were the area under the plasma concentration-time curve (AUC), peak plasma concentrations (C max ) and trough plasma concentrations (C min ). The quality of the included studies was assessed using Cochrane's risk of bias tool, Newcastle-Ottawa Scale (NOS) and a modified risk of bias tool for pharmacokinetic before-and-after studies. Results and discussion: Sixteen studies were included in this review: three randomized controlled trials (RCTs), five single-arm before-after studies (SBAs), six cohort studies and two case reports. All studies except case reports had moderate to high quality. Of the 11 inducers reviewed, efavirenz, ritonavir (chronic use), phenytoin, rifampin and rifabutin significantly decreased mean AUC and C max of voriconazole; St John's wort significantly decreased only mean AUC; rifampin, rifabutin, phenobarbital and carbamazepine significantly decreased mean C min . Etravirine and Ginkgo biloba did not reveal any such influence. The influence of glucocorticoids may depend on its type and dose. What is new and conclusions: To conclude, the combination use of high-dose efavirenz, high-dose ritonavir, St John's wort, rifampin, phenobarbital, or carbamazepine with voriconazole is contraindicated as instructed in the drug label. Low-dose efavirenz, low-dose ritonavir, rifabutin and phenytoin may be used together with voriconazole provided TDM and dose adjustment of voriconazole. Moreover, this study shows there is low risk of drug-drug interactions when voriconazole is co-administered with etravirine or G. biloba; however, whether the use of glucocorticoids has a clinically significant effect on voriconazole still requires more evidence. This study also highlights the lack of clinical studies and future high-quality studies assessing the influence of CYP450 inducers on voriconazole. PK parameters and dosing optimization should be designed to provide a more definitive answer regarding the necessity of TDM and the recommendations for dose adjustment of voriconazole.
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WHAT IS KNOWN AND OBJECTIVES
Voriconazole is a second-generation broad-spectrum triazole antifungal agent with activity against a wide range of yeasts and filamentous fungi. 1 It is commonly used to treat severe invasive fungal infections, which often occur in immunocompromised patients and patients in intensive care units (ICU). 2 The pharmacokinetics of voriconazole are highly variable between individuals, and concentrations may vary 100-fold even in healthy volunteers. 3 Voriconazole is known to exhibit nonlinear pharmacokinetics and is metabolized primarily via CYP2C19 and, to a lesser extent, CYP2C9 and CYP3A4. [4] [5] [6] Therefore, CYP450 genetic polymorphisms and CYP-mediated drug interactions are important determinants of interindividual variability of voriconazole exposure.
Polymorphisms of CYP2C19 may play an important role in voriconazole pharmacokinetics, whereas polymorphisms of CYP3A4 are not considered clinically relevant, as the affinity of voriconazole for CYP3A4 is about 50-fold lower compared with its affinity for CYP2C19. 5 The CYP2C9 genotypic variations do not significantly influence one's exposure to voriconazole, as only a small fraction of the drug is metabolized through this enzymatic pathway. 7 In homozygous poor metabolizers of CYP2C19, the C max and AUC values of voriconazole are 2-5 times higher than those in extensive metabolizers. 8 The prevalence of CYP2C19 gene polymorphisms differs by race, with 20-30% of the Asian population and 2-3% of Caucasians being homozygous poor metabolizers. 9 The variability of voriconazole exposure is of great concern. A number of studies have demonstrated the relationship between voriconazole trough plasma concentration and clinical efficacy and toxicity.
Co-administration with a known CYP450 inducer may decrease the systemic exposure of voriconazole to a level below the target range, potentially leading to treatment failure. To achieve the maximum attainable therapeutic effect when treating invasive fungal disease, it is important to be aware of the impact, whether theoretical or proven, of drug-drug interactions. The influence of some CYP450 inducers on the pharmacokinetics of voriconazole has been described on the drug label and in previous reviews; 2, 14 however, a systematic review with quantitative description of pharmacokinetic changes was lacking. The aim of this review was to thoroughly summarize current available evidence regarding the influence of concurrent use of CYP450 inducers on the pharmacokinetics of voriconazole, and give suggestions on how to cope with each specific interactions as clearly as possible, for example whether the concomitant use of a certain inducer should be avoided or whether dosage adjustment of voriconazole is required.
METHODS

Data sources
Eligible trials were identified through electronic searches, which were performed in Medline, Embase, Cochrane Library, Clinicaltrials.gov and three Chinese databases (CNKI, CBM and WanFang) from its inception until January 2016. We used the solo term 'voriconazole' as a search strategy.
Study selection
Electronic search results were screened by a group of pharmacists well-trained in the field of systematic reviews. Afterwards, two reviewers (TL, WL) independently assessed titles and abstracts of the screened citations focusing on the combination use of voriconazole and CYP450 inducers. Studies were included if (i) study subjects were either healthy volunteers or patients; (ii) they potentially involved concomitant use of voriconazole with CYP450 inducers; and (iii) they compared the PK parameters of voriconazole alone to voriconazole with concomitant use of CYP450 inducers. No language limitation was set although we additionally searched Chinese literature databases. There were no restrictions with regard to dose, duration or route of administration. Exclusion criteria were as follows: (i) concomitant use of voriconazole with both CYP450 inducers and CYP450 inhibitors without conducting a multivariate analysis; (ii) duplicate publication; (iii) data not available; and (iv) case reports, if higher quality studies were found. Full text of potentially relevant articles was retrieved and assessed for inclusion by the same reviewers (TL, WL) using the criteria above. Disagreement was resolved by consensus after the input of the third author (KC), who had the final decision.
Data extraction
Two reviewers (TL, WL) independently extracted data from the included studies. The authors were contacted if additional information was required from the studies. From each study, the information extracted included study characteristics (author, year of publication, study design, subject, sample size for each group); participants' age, gender, weight and body mass index (BMI); medication regimen (name of drug, dose, route, frequency and duration of treatment); PK parameters (C max , C min , AUC), as well as sample size based on power calculation, withdrawal from the study and failure to follow-up.
Quality assessment
The quality of the included RCTs was assessed with Cochrane Collaboration's risk of bias tool, which includes the following domains: random sequence generation, allocation concealment, blinding (of participants, personnel and outcome assessment), incomplete outcome data, selective outcome reporting and other bias. Each criterion was judged according to low risk of bias; high risk of bias or uncertainty over the degree of bias (unclear). 15 We used a self-developed tool, Modified Risk of Bias for Pharmacokinetic Before-and-After Studies, for assessing the risk of bias of SBAs as there was no specific quality assessment standard for them. The criteria were based on the Cochrane risk of bias tool, criteria described by the Cochrane Effective Practice and Organization of Care (EPOC) Group and a quality appraisal tool for crossover studies 16 including random sequence generation, carry-over effect, incomplete outcome data, selective reporting, comparability and other bias. Additionally, we added the item 'pharmacokinetic design' to ensure that their pharmacokinetic designs (e.g. blood sampling time, calculation of AUC, pharmacokinetic model) were appropriate. The new tool also scored as low risk, high risk or unclear risk of bias. For cohort studies, we used the Newcastle-Ottawa Scale (NOS), which addressed representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, demonstration that the outcome of interest was not present at the start of the study, cohorts received a similar voriconazole dose and were comparable on other factors (age, gender, race, BMI, gene polymorphism, other co-administration drug), assessment of outcome, follow-up long enough for outcomes to occur and adequacy of follow-up of the cohorts. 17 Authors (TL, WL) independently assessed the risk of bias and resolved disagreements by consensus with a third author (KC). As there was no generally accepted criteria to assess the quality of case reports, we did not use any criteria to assess their risk of bias, however, compared with the prospective pharmacokinetic studies; they deserved a high risk of bias. The quality assessment was carried out only for the studies with full text.
Data analysis
We pooled data from studies that were sufficiently homogenous and with the same study design. Meta-analysis was conducted using Review Manager (Revman Version 5Á2, Copenhagen, Denmark). Results of the meta-analysis were presented as weighted mean differences with 95% confidence intervals (CI) for continuous outcomes. I 2 values of 30-60% and over 75% represented moderate and considerable heterogeneity, respectively. 18 As for the studies not eligible for meta-analysis, the 95% CI of PK parameters was calculated according to the mean, standard deviation and case number provided in the studies. When significant statistical differences were shown between the two groups, the minimal percentage of intervention group to control group was calculated by dividing the upper limit of the 95% CI of the intervention group by the lower limit in control group. We performed subgroup analyses to examine different interventions (i.e. dosing regimens).
RESULTS
Literature searches and study inclusion
The search of electronic databases (performed in Jan, 2016) resulted in 12 264 records, of which 2220 were duplicate and 9175 were not relevant, judging by reading titles and abstracts (Fig. 1) . Of the remaining 869 records for further screening, 471 records were excluded for not meeting the inclusion criteria, leaving 398 records for detailed review. We excluded 382 articles after reviewing the full text. Eventually, 16 articles were identified to meet the inclusion criteria. The search of Clinicaltrails.gov resulted in 31 records, but none of them met the inclusion criteria. Of the 16 included studies, three were RCTs, five SBAs, six cohort studies and two case reports. Eleven CYP450 inducers were studied, including efavirenz, ritonavir, etravirine, phenytoin, St John's wort, G. biloba, rifampin, rifabutin, phenobarbital, carbamazepine and glucocorticoids. Interventional studies were conducted in healthy volunteers, and observational studies were conducted in patients who received voriconazole for prophylaxis or treatment of fungal infections. Sample size ranged from 1 to 209, and all subjects were adults. Details of the included studies are shown in Table 1 : 'Basic characteristics of included studies'. The dose and duration of voriconazole therapy alongside the CYP450 inducers varied across different studies ( Table 1) .
Most of the included studies reported AUC and C max , five of them reported C min , and three studies only described the changes of PK parameters of voriconazole but provided no data. C max and C min were obtained directly from the original data. AUC from zero to infinity (AUC 0-∞ ) and AUC s (s = dosing interval) were collected for single-dose and multiple-dose use of voriconazole. A meta-analysis was not able to be performed due to significant heterogeneity and lack of data. Table 2 provides a summary of the quality assessments for each study type. Of the three included RCTs, one study had high risk of selection bias due to the open design that did not use random sequence generation and allocation concealment. All three RCTs reported PK parameters. They provided a clear description of dropouts and accounted for patients with missing data in the analyses. The five SBAs were all a fixed-sequence design in which voriconazole was given alone and then with CYP450 inducers; therefore, carry-over effect was judged to be low risk. As to comparability, all five SBAs were judged to have a low risk of bias as they included only healthy volunteers. Three cohort studies had low to moderate quality, as they failed to present voriconazole dosage or baseline characteristics of participants between groups. The other two cohort studies had high quality.
Risk of bias in included studies
Effects of CYP450 inducers
Efavirenz. Two SBA studies reported C max and AUC of voriconazole used alone or with efavirenz. The mean voriconazole AUC s and C max were decreased to 44Á94% and 61Á25% compared to 100% in voriconazole monotherapy, respectively, during combination use with efavirenz 400 mg qd for 9 days (Liu et al.). Another study (Damle et al.) decreased efavirenz dose to 300 mg q24h and increased voriconazole dose to 300 mg q12h from the standard dose of 200 mg q12h. They reported that both the AUC s and C max of voriconazole were still lower in the concomitant efavirenz group than in the voriconazole standard-dose monotherapy group, but there was no statistically significant difference. However, 400 mg q12h of voriconazole could provide similar AUC s and C max compared with standard-dose monotherapy (Table 3) .
Ritonavir. Two studies (one RCT, one SBA) reported C max and AUC of voriconazole when used alone or with ritonavir. In the SBA study, which included 14 healthy volunteers (Liu et al.), the mean voriconazole AUC s and C max were decreased to 29Á36% and 51Á52% compared to 100% in voriconazole monotherapy respectively, during combination use of ritonavir 400 mg bid for 10 days. The above parameters were slightly higher in the low-dose chronic ritonavir use (100 mg bid for 10 days) group, with no significant differences. Another study (Mikus et al.) reported that short-term ritonavir therapy (300 mg bid for 2 days) resulted in an increase in AUC 0-∞ and C max of single-dose voriconazole (Table 3) .
Etravirine. Only one SBA study (Kakuda et , compared to 100% in voriconazole monotherapy. C max of voriconazole was also decreased; however, no significant statistical differences were found when calculated from the 95% confidence interval (Table 3) .
Ginkgo biloba. Only one RCT (Lei et al.), including 14 healthy volunteers, evaluated the influence of G. biloba on C max and AUC of voriconazole. Genotyping of CYP2C19 was performed in this study. Ginkgo biloba pretreatment for 12 days did not significantly affect C max and AUC 0-∞ of single-dose voriconazole in either CYP2C19 homozygous extensive metabolizers (2C19*1/*1) or poor metabolizers (2C19*2/*2) ( Table 3 ).
Glucocorticoids. Six cohort studies investigated the effect of glucocorticoids on the pharmacokinetics of voriconazole. However, different studies showed different results. Gautier et al. 30 showed treatment with glucocorticoids had no impact on voriconazole C min (P = 0Á2) ( Table 3 ). Three studies (Eiden et al., Dolton et al., Naito et al.) 28, 29, 31 reported that glucocorticoids slightly elevated the metabolism of voriconazole, although it did not affect the plasma exposure of voriconazole. Two studies (Dolton et al., Cojutti et al.) 27, 34 found that co-administration of voriconazole with glucocorticoids led to a significant decrease in normalized voriconazole C min (P < 0Á001), and co-administration of methylprednisolone and dexamethasone had a greater effect on voriconazole concentration than did prednisone or prednisolone co-administration (Table 3) .
Rifampin and rifabutin. One cohort study (Cojutti et al.) 34 revealed that co-administration of rifampin was associated with an average decrease in voriconazole C min in a multivariable analysis (P = 0Á004) ( Table 3 ). Two case reports described the voriconazole Table 3 . PK profile when co-administered with rifabutin. Debraine et al.
32
described a 48-year-old patient whose voriconazole C min was constantly under therapeutic range (<0Á15 lg/mL) despite aggressive dosage (400 then 600 mg bid) of voriconazole being administered. However, when rifampin was replaced by rifabutin, voriconazole C min was increased to 1Á81 lg/mL after 5 days. Schwiesow et al. 33 described a 30-year-old woman who received intravenous voriconazole 300 mg every 12 h together with oral rifabutin 150 mg/day. Her voriconazole C min was 0Á12 lg/mL, but after voriconazole dosage was increased to 300 mg orally three times/day, C min was within the target range (0Á68 lg/mL).
Phenobarbital and carbamazepine. Cojutti et al. described an average decrease in voriconazole C min through multivariate analysis when patients received either phenobarbital (P = 0Á006) or carbamazepine (P = 0Á051) in combination with voriconazole therapy (Table 3) .
DISCUSSION
Explanation for findings
Our systematic review describes the influence of various CYP450 inducers on the PK parameters of voriconazole in different populations. The results indicate a significant decrease in voriconazole exposure following co-administration with efavirenz, ritonavir (chronic use), phenytoin, St John's wort, rifampin, rifabutin, phenobarbital and carbamazepine. This decrease is most likely due to CYP2C19 and CYP2C9 enzyme induction, and less to CYP3A4 induction, as CYP3A4 is not a major pathway for voriconazole metabolism.
Phenytoin, rifampin and carbamazepine are widely known as hepatic CYP450 enzyme inducers. All three drugs could strongly induce CYP3A4 (≥80% decrease in substrates' AUC), whereas phenytoin and rifampin also moderately induce CYP2C19 and CYP2C9 (50-80% decrease in substrates' AUC), and carbamazepine only moderately induces CYP2C9. [35] [36] [37] [38] Rifabutin's spectrum of enzyme induction appears to be similar to, but less potent than, rifampin (~40% as potent). [38] [39] [40] [41] Phenobarbital is a typical enzyme inducer of CYP2C9 and CYP3A4, which presents a weak induction effect (20-50% decrease in substrates' AUC)
. 38, [42] [43] [44] Several studies have shown that repeated doses of efavirenz and St John's wort had a significant induction effect on both CYP2C19 and CYP3A4 in vivo. [45] [46] [47] [48] [49] [50] [51] [52] [53] Thus, in our study these two drugs may enhance voriconazole metabolism through the induction of the above enzymes. In previous studies, ritonavir has been found to be a potent inhibitor of CYP3A4. [54] [55] [56] It also appears to induce CYP3A4, CYP2C9 and CYP2C19, 57, 58 depending on the course of treatment. The results of our study using concurrent ritonavir were controversial. They show that 2-day concomitant ritonavir use increased the exposure of voriconazole, whereas 10-day ritonavir decreased the exposure of voriconazole, probably due to the weak induction of CYP2C19 and CYP2C9 in ritonavir short-term use being offset by CYP3A4 inhibition. However, enzyme induction became stronger and presented as the dominant effect in long-term use. It may take 10-14 days, or even longer, for enzyme induction to reach its full effect. 59 Enzyme inhibition, on the other hand, is instantaneous and dependent on the dose of the drug. 59 In co-administration with efavirenz, significant effects on voriconazole pharmacokinetics were seen, even when the efavirenz dose (300 mg or 400 mg qd) was lower than the standard therapeutic dose (600 mg qd). One study did demonstrate that combination use of voriconazole 400 mg q12 h with efavirenz 300 mg q24 h resulted in similar voriconazole exposure to that achieved by voriconazole monotherapy at 200 mg q12 h. During co-administration with phenytoin, similar to efavirenz, it is recommended that oral voriconazole doses should be increased to 400 mg q12 h based on the RCT included. However, there was only one SBA study for efavirenz dose adjustment and one RCT for phenytoin with a fairly small population, so these findings were not sufficient to support clinical dose adjustment.
In vitro and in vivo studies have identified an inductive effect of glucocorticoids on CYP2C19 and CYP2C9, 60, 61 but the effect appears to be less than that of other known inducers such as rifampin and phenytoin. 27 In addition, CYP3A4, which glucocorticoids have been shown to induce at higher doses, 62 also contributes to the metabolism of voriconazole. 6, 63 In our study, the influence of glucocorticoids on the PK parameters of voriconazole shows conflicting results, which could be explained by the weak inductive effect of glucocorticoids, as well as heterogeneity of the study populations and the type and dose of the glucocorticoids.
The results demonstrated that the effects of etravirine or G. biloba on voriconazole pharmacokinetics were not expected to be clinically relevant, probably due to the weak induction of CYP enzymes, or biphasic effect. Etravirine is both a weak inducer of CYP3A4 and a weak inhibitor of CYP2C9 and CYP2C19. 64 In in vivo studies, G. biloba induced CYP2C19 and CYP2C9 at higher doses 65, 66 rather than the lower dose of Gingko biloba used in the included study, which may explain the weak impact on voriconazole exposure.
In drug labels, the concomitant administration of voriconazole with high-dose efavirenz, high-dose ritonavir, St John's wort, rifampin, carbamazepine and long-acting barbiturates is contraindicated. This review provided more detailed data to demonstrate that systemic exposure of voriconazole is significantly reduced, or is expected to be reduced, following co-administration with these medications. Although rifabutin is recommended as a contraindication in the drug label, there are case reports showed that the enzyme induction effect of rifabutin was less potent than rifampin, and C min of voriconazole could be maintained within normal therapeutic range when co-administered with rifabutin. Therefore, the cases suggested that rifabutin could be a substitute of rifampin under voriconazole TDM. Carbamazepine and phenobarbital are also contraindicated in the drug label, although this contraindication is based only on theoretical mechanisms and no in vivo or in vitro data were provided. This review included one cohort study documenting the induction effect of carbamazepine and phenobarbital on voriconazole, providing supporting evidence to drug labels.
Furthermore, there are three drugs that are not listed in the 'drug-drug interaction' item on voriconazole drug label, including glucocorticoids, etravirine and G. biloba. Our study revealed various extents of reduced systemic exposure of voriconazole following co-administration with glucocorticoids, except for one cohort study showing no difference; therefore, further studies are needed to confirm the influence, and to provide detailed information about whether TDM and dose adjustment are necessary. Meanwhile, there is minor or insignificant pharmacokinetic influence of etravirine or G. biloba on voriconazole, so dosage adjustment is not required. As most non-nucleoside reverse transcriptase inhibitors (NNRTI) are inducers or inhibitors of CYP450, and they could significantly influence PK profile of voriconazole, etravirine may be a choice of comedication. Extracts of G. biloba are widely used as over-the-counter products, and our review does not prove a high risk of potential voriconazole treatment failure with concomitant use. However, as herbal medicines are becoming increasingly popular in recent years, the potential for drug-drug interactions should be watched more carefully. For clinical interpretations, it should be kept in mind that much of the data presented in our review is from studies of healthy volunteers or a limited number of patients, and so it may not be completely compatible with clinical settings.
Appropriateness of the study designs of included studies
In total, 16 studies with 899 participants were included in this review. We included both controlled studies and non-controlled studies as we aimed to provide all available evidence of recognized CYP450 inducers that would not be adequately addressed with controlled studies alone.
Besides what was assessed by risk of bias tool, we decided that crossover design was suitable for pharmacokinetic studies carried out in healthy volunteers and the carry-over effect can be eliminated completely by the washout period. However, lacking crossover design, SBAs could not eliminate the influence of other potential factors and may result in high risk of bias. Overall, we judged that the quality of the available evidence was moderate to high, except for rifabutin whose evidence was weakened by the lack of relevant RCTs or SBAs.
WHAT IS NEW AND CONCLUSION
To the best of our knowledge, this is the first systematic review investigating the influence of CYP450 inducers on voriconazole PK parameters. The results provided more detailed data to characterize the co-administration of voriconazole with CYP450 inducers. To conclude, the combination use of high-dose efavirenz, high-dose ritonavir, St John's wort, rifampin, phenobarbital, and carbamazepine is contraindicated as instructed on the drug label. Lowdose efavirenz, low-dose ritonavir, rifabutin and phenytoin may be used together with voriconazole provided TDM and dose adjustment of voriconazole is performed. Moreover, the present study shows there is low risk of drug-drug interactions when voriconazole is co-administered with etravirine or G. biloba. Whether the use of glucocorticoids has a clinically significant effect on voriconazole still requires more evidence. This study also highlights the lack of clinical studies and future high-quality studies assessing the influence of CYP450 inducers on voriconazole PK parameters and dosing optimization should be designed to provide a more definitive answer regarding the necessity of TDM and the recommendations for dose adjustment of voriconazole.
